Publicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (211)

2024

  1. Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

    JHEP Reports, Vol. 6, Núm. 1

  2. Astrocytic GLUT1 reduction paradoxically improves central and peripheral glucose homeostasis

    Science Advances , Vol. 10, Núm. 42

  3. Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

    Blood Cancer Journal, Vol. 14, Núm. 1

  4. Intratumoral NK cell delivery combined with neutralization of the NKG2A pathway as treatment for solid cancer

    Genes and Immunity, Vol. 25, Núm. 5, pp. 437-439

  5. MCPIP1 Inhibits Hepatic Stellate Cell Activation in Autocrine and Paracrine Manners, Preventing Liver Fibrosis

    Cellular and Molecular Gastroenterology and Hepatology, Vol. 17, Núm. 6, pp. 887-906

  6. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  7. SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

    Cell Reports, Vol. 43, Núm. 3

  8. Sensitizing cholangiocarcinoma to chemotherapy by inhibition of the drug-export pump MRP3

    Biomedicine and Pharmacotherapy, Vol. 180

2023

  1. A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease

    Parkinsonism and Related Disorders, Vol. 110

  2. Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes

    The Lancet. Oncology, Vol. 24, Núm. 1, pp. 91-106

  3. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

  4. Loss of the matrix metalloproteinase-10 causes premature features of aging in satellite cells

    Frontiers in Cell and Developmental Biology, Vol. 11

  5. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

  6. Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi

    Molecular Therapy Nucleic Acids, Vol. 34

  7. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

    Bone Marrow Transplantation

  8. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

  9. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma

    Journal for immunotherapy of cancer, Vol. 11, Núm. 2

2022

  1. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

  2. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

  3. Genetic Inactivation of Free Fatty Acid Receptor 3 Impedes Behavioral Deficits and Pathological Hallmarks in the APPswe Alzheimer’s Disease Mouse Model

    International Journal of Molecular Sciences, Vol. 23, Núm. 7